Oslo, Norway, 23rd from August 2024
Vistin Pharma ASA (VISTN) today announces financial results for the second quarter of 2024.
Sales for the second quarter were NOK 106 million compared to NOK 107 million in the second quarter of 2023. Sales volume for the quarter increased by 4% compared to the second quarter of 2023; sales adjusted for currency effects increased by 1%. Sales for the first half of 2024 were NOK 210 million compared to NOK 208 million in the same period last year.
EBITDA for the second quarter was NOK 27 million compared to NOK 20 million in the second quarter of 2023, an increase of 40%. EBITDA was positively impacted by product mix, favorable material costs and good cost control during the quarter. EBITDA for the first half of 2024 was NOK 48 million compared to NOK 34 million during the year 2023, an increase of 42%.
Net profit was NOK 19.2 million in the second quarter of 2024. Net profit had a positive impact of approximately NOK 2.5 million in the quarter due to the fair value of future foreign exchange cash flow hedging contracts (unrealized gain – no cash effect in the quarter).
Cash dividend of NOK 0.50 per share will be paid in June 2024. An additional dividend of NOK 0.50 per share is expected to be paid in the fourth quarter.
The second quarter conference call, which will take place today, August 23, at 8:30 a.m. (CET), will be available via webcast and audio through the following access points:
Webcast:
https://edge.media-server.com/mmc/p/v93s3oau
Telephone conference (online registration):
https://register.vevent.com/register/BIe6d25489e7ce45c18e8661e4d04d1d9a
The conference call will be held in English.
The Q2 report and presentation can be found in the appendix. The report will also be available on www.vistin.com.
*****
For further information please contact:
Alexander Karlsen
Chief Financial Officer
+47 97 05 36 21
[email protected]
This information is subject to the disclosure requirements under sections 5–12 of the Norwegian Securities Trading Act.
Facilities
